HBV

[키워드] activity adverse event allergic reaction anti-SARS-CoV-2 anti-SARS-CoV-2 antibody Anti-SARS-CoV-2 plasma Anti-viral blinded Blood blood product center Chest radiography Clinical improvement Clinical outcome clinical status clinical trial clinician collected Columbia University control arm convalescent plasma coronavirus COVID-19 COVID-19 symptom criteria cumulative Date defined Dilution discharge dissemination Donor ECMO Efficacy Efficacy and safety element evaluate Evaluating Evidence extracorporeal membrane oxygenation hazard hazard ratio HBV HCV HIV hospital Hospitalized hospitalized patient IgA deficiency immune incidence include Infection Influenza Invasive mechanical ventilation mechanical ventilation multi-organ failure nasopharyngeal Nasopharyngeal swab New York Non-invasive number objective occur oropharyngeal swab outcome oxygen saturation participant Participants patients hospitalized PCR test PCR-negative per-protocol analysis peripheral capillary plasma platform post-hoc analysis Pregnancy primary endpoint protocol randomization Randomized Randomized controlled trial randomized, controlled trial randomly permuted block receive Registered Remdesivir requiring high-flow oxygen requiring supplemental oxygen Research Respiratory failure retrospective Ritonavir safety endpoint Sample size SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection screened Serious Adverse Event seven-point ordinal scale severe COVID-19 severe SARS-CoV-2 severely ill adult single-center spike trimer SpO2 status study participant study period Study protocol supplemental oxygen tested therapy transfused Treatment treatment for COVID-19 Trial undergo USA Version Volunteer Wald test website with COVID-19 World Health Organization ZIKV
[DOI] 10.1186/s13063-020-04422-y PMC 바로가기 [Article Type] Letter